Objective Creative thinking requires a combination of originality, flexibility, and usefulness. Several reports described enhanced artistic creativity in Parkinson disease (PD) patients treated with dopaminergic agents. We aimed to examine PD patients' ability to perform creativity tasks compared to healthy controls and to verify whether creativity is related to an impulse control disorder (ICD) as a complication of dopaminergic therapy. Methods Right-handed PD patients treated with dopamine agonists and/or levodopa, and age- and education- matched neurologically healthy controls were assessed using the Montreal Cognitive Assessment, semantic verbal fluency, Beck Depression Inventory, and Questionnaire for Impulsive-Compulsive Disorders in Parkinson Disease Rating Scale (QUIP-RS). Creativity assessment included Comprehension of Novel Metaphors (CNM), Remote Association Test, and Tel Aviv Creativity Test (TACT). Groups were compared using analyses of variance, t tests, and correlation analyses. Results Twenty-seven PD patients (age, mean ± standard deviation = 62 ± 7 years; education = 16 ± 3 years; disease duration = 5.8 ± 3.9 years) and 27 controls (age = 59 ± 9 years; education 17 ± 3 years) participated. PD patients performed significantly better than controls in divergent thinking tasks; specifically, the TACT-Visual for both fluency (33.48 ± 11.83 vs 25.59 ± 10.27, p = 0.034) and quality (15.78 ± 7.6 vs 11.19 ± 6.22, p = 0.025). Comprehension of Novel Metaphors was better in PD patients vs controls (0.71 ± 0.23 vs 0.55 ± 0.29, p = 0.04). QUIP-RS scores did not correlate with creativity measures. Interpretation PD patients treated with dopaminergic drugs demonstrated enhanced verbal and visual creativity as compared to neurologically healthy controls. This feature was unrelated to ICD. Dopaminergic agents might act through the reduction of latent inhibition, resulting in widening of the associative network and enriched divergent thinking. Ann Neurol 2014;75:935-942
展开▼
机译：客观创造性思维需要独具匠心，具有灵活性和实用性。一些报告描述了用多巴胺能药物治疗的帕金森病（PD）患者的艺术创造力增强。我们旨在检查PD患者与健康对照组相比执行创造力任务的能力，并验证创造力是否与作为多巴胺能疗法并发症的冲动控制障碍（ICD）相关。方法使用蒙特利尔认知评估，语义言语流利性，贝克抑郁量表和帕金森氏冲动障碍问卷调查评估接受过多巴胺激动剂和/或左旋多巴治疗的右撇子PD患者以及年龄和教育程度相匹配的神经系统健康对照疾病分级量表（QUIP-RS）。创造力评估包括对新隐喻的理解（CNM），远程联想测验和特拉维夫创造力测验（TACT）。使用方差分析，t检验和相关分析比较各组。结果27名PD患者（年龄，平均±标准差= 62±7年;教育= 16±3年;病程= 5.8±3.9年）和27名对照（年龄= 59±9年;教育17±3年） ）参加。 PD患者在发散思维任务方面的表现明显好于对照组。具体来说，TACT-Visual的流畅度（33.48±11.83 vs 25.59±10.27，p = 0.034）和质量（15.78±7.6 vs 11.19±6.22，p = 0.025）。 PD患者对新隐喻的理解要好于对照组（0.71±0.23 vs 0.55±0.29，p = 0.04）。 QUIP-RS得分与创造力度量不相关。解释与神经系统健康对照相比，用多巴胺能药物治疗的PD患者表现出增强的言语和视觉创造力。此功能与ICD无关。多巴胺能药物可能通过减少潜在的抑制作用而起作用，从而导致联想网络的扩大和丰富的分歧思维。 Ann Neurol 2014; 75：935-942
展开▼
